Menu
Back to User profile » Prof. Dr. Dierk Thomas
Papers published by Prof. Dr. Dierk Thomas:
Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation
Rahm AK, Gramlich D, Wieder T, Müller ME, Schoeffel A, El Tahry FA, Most P, Heimberger T, Sandke S, Weis T, Ullrich ND, Korff T, Lugenbiel P, Katus HA, Thomas D
Pharmacogenomics and Personalized Medicine 2021, 14:579-590
Published Date: 20 May 2021
COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Katus HA, Ehlermann P, Doesch AO
Clinical Epidemiology 2018, 10:1359-1369
Published Date: 27 September 2018
Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO
Therapeutics and Clinical Risk Management 2017, 13:1399-1407
Published Date: 13 October 2017
Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2017, 11:1827-1837
Published Date: 19 June 2017
The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Therapeutics and Clinical Risk Management 2017, 13:287-297
Published Date: 8 March 2017
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2016, 10:677-686
Published Date: 16 February 2016
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action
Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP,
Drug Design, Development and Therapy 2015, 9:867-877
Published Date: 16 February 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:93-102
Published Date: 17 December 2014
Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action
Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP
Drug Design, Development and Therapy 2014, 8:2263-2271
Published Date: 7 November 2014
The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation
Schmidt C, Kisselbach J, Schweizer PA, Katus HA, Thomas D
Vascular Health and Risk Management 2011, 7:193-202
Published Date: 31 March 2011